Connect Biopharma Holdings Limited — Form 6-K Summary
Business context and reporting period
This Form 6-K, dated August 19, 2022, reports a Nasdaq listing compliance matter for Connect Biopharma Holdings Limited, a foreign private issuer that files annual reports on Form 20-F. The filing does not provide operating or financial results.
Key financial metrics and liquidity
The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, guidance, or other financial metrics.
Material changes versus the prior comparable period
- On June 16, 2022, Nasdaq notified the Company that its American Depositary Shares had failed to maintain the required minimum closing bid price of $1.00 for 30 consecutive business days.
- On August 17, 2022, Nasdaq notified the Company that it had regained compliance. The ADSs maintained a minimum closing bid price of at least $1.00 for 10 consecutive trading days through August 16, 2022.
- Nasdaq closed the matter, and no further compliance action was identified in this filing.
Guidance, outlook, risks, contingencies, and unusual items
The principal unusual item is the resolved Nasdaq minimum bid price deficiency. Continued compliance with Nasdaq listing requirements remains relevant, but the filing provides no additional outlook, risk discussion, or contingency.
The Form 6-K is incorporated by reference into the Company’s Form F-3 registration statement and Form S-8 registration statements, subject to subsequent filings or reports.
Facts investors should verify
- Whether the ADS price continued to satisfy Nasdaq’s minimum bid price requirement after the reported compliance period.
- Any subsequent Nasdaq notices or listing-status developments.
- The Company’s latest Form 20-F, Form 6-K, and other filings for financial condition, cash runway, operating results, and financing needs, which are not addressed here.